NCT05454956Phase 2Completed

Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGD

Study sponsor: Tarsus Pharmaceuticals, Inc. · TARS

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2023-05-18Actual

Enrollment · participants39Actual

Source updated2025-10-01Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2025-10-01 · 1 field changed

Actual enrollment decreased by 1 participants

− Before

~~40 participants (actual)~~

+ After

39 participants (actual)

Check registry source